دورية أكاديمية
Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.
| العنوان: | Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Nassar M; Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals/Queens, New York City, New York, USA., Abosheaishaa H; Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals/Queens, New York City, New York, USA., Singh AK; Department of Diabetes & Endocrinology, GD Hospital & Diabetes Institute, Kolkata, India., Misra A; Chairman, Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Diabetes Foundation (India), and National Diabetes Obesity and Cholesterol Foundation (NDOC), New Delhi, India., Bloomgarden Z; Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA. |
| المصدر: | Journal of diabetes [J Diabetes] 2023 Feb; Vol. 15 (2), pp. 86-96. Date of Electronic Publication: 2023 Jan 23. |
| نوع المنشور: | Meta-Analysis; Systematic Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101504326 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1753-0407 (Electronic) Linking ISSN: 17530407 NLM ISO Abbreviation: J Diabetes Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Richmond, Vic. : Blackwell Publishing Asia, 2009- |
| مواضيع طبية MeSH: | Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/drug therapy , Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use , COVID-19*/epidemiology , COVID-19*/complications , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Metformin*/therapeutic use, Humans ; Hypoglycemic Agents/therapeutic use ; Glucagon-Like Peptide-1 Receptor |
| مستخلص: | Background: Patients with diabetes are more likely to suffer COVID-19 complications. Using noninsulin antihyperglycemic medications (AGMs) during COVID-19 infection has proved challenging. In this study, we evaluate different noninsulin AGMs in patients with COVID-19. Methods: We searched Medline, Embase, Web of Science, and Cochrane on 24 January 2022. We used the following keywords (COVID-19) AND (diabetes mellitus) AND (antihyperglycemic agent). The inclusion criteria were studies reporting one or more of the outcomes. We excluded non-English articles, case reports, and literature reviews. Study outcomes were mortality, hospitalization, and intensive care unit (ICU) admission. Results: The use of metformin rather than other glucose-lowering medications was associated with statistically significant lower mortality (risk ratio [RR]: 0.60, 95% confidence interval [CI]: 0.47, 0.77, p < .001). Dipeptidyl peptidase-4 inhibitor (DPP-4i) use was associated with statistically significantly higher hospitalization risk (RR: 1.44, 95% CI: 1.23, 1.68, p < .001) and higher risk of ICU admissions and/or mechanical ventilation vs nonusers (RR: 1.24, 95% CI: 1.04, 1.48, p < .02). There was a statistically significant decrease in hospitalization for SGLT-2i users vs nonusers (RR: 0.89, 95% CI: 0.84-0.95, p < .001). Glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a statistically significant decrease in mortality (RR: 0.56, 95% CI: 0.42, 073, p < 0.001), ICU admission, and/or mechanical ventilation (RR: 0.79, 95% CI: 0.69-0.89, p < .001), and hospitalization (RR: 0.73, 95% CI: 0.54, 0.98, p = .04). Conclusions: AGM use was not associated with increased mortality. However, metformin and GLP-1RA use reduced mortality risk statistically significantly. DPP-4i use was associated with a statistically significant increase in the risk of hospitalization and admission to the ICU. (© 2023 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.) |
| References: | Diabetes Metab Syndr. 2022 Jun;16(6):102512. (PMID: 35660932) Clin Obes. 2021 Apr;11(2):e12439. (PMID: 33423388) Int J Clin Pract. 2021 Nov;75(11):e14833. (PMID: 34510676) J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109. (PMID: 33945610) Diabetes Metab. 2022 Jan;48(1):101307. (PMID: 34863934) Diabetes Obes Metab. 2021 Feb;23(2):589-598. (PMID: 33200501) Pharmacol Ther. 2020 May;209:107503. (PMID: 32061923) Endocrinology. 2013 Dec;154(12):4503-11. (PMID: 24092637) J Diabetes. 2023 Feb;15(2):86-96. (PMID: 36690377) Diabetes Metab. 2021 Sep;47(5):101216. (PMID: 33309936) Diabetes Metab Syndr. 2021 May-Jun;15(3):777-782. (PMID: 33838614) Diabetologia. 2021 Apr;64(4):778-794. (PMID: 33599800) Diabetes Care. 2021 Apr;44(4):e64-e66. (PMID: 33547204) Diabetes Metab. 2020 Nov;46(6):423-426. (PMID: 32750451) Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-550. (PMID: 32334646) Front Pharmacol. 2020 Aug 07;11:1161. (PMID: 32848769) Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. (PMID: 34302745) Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. (PMID: 32573903) Am J Trop Med Hyg. 2020 Jul;103(1):69-72. (PMID: 32446312) Diabetes Care. 2021 Jul;44(7):1564-1572. (PMID: 34135013) Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102268. (PMID: 34562865) J ASEAN Fed Endocr Soc. 2021;36(2):133-141. (PMID: 34966196) Expert Opin Drug Saf. 2021 Nov;20(11):1309-1315. (PMID: 34424130) Front Immunol. 2020 Jul 22;11:1582. (PMID: 32793223) Diabetologia. 2017 Sep;60(9):1630-1638. (PMID: 28770328) Biomedicines. 2022 Oct 19;10(10):. (PMID: 36289885) J Diabetes Res. 2017;2017:9584278. (PMID: 28791311) BMC Med. 2020 Nov 16;18(1):359. (PMID: 33190637) Nat Rev Endocrinol. 2021 Jan;17(1):11-30. (PMID: 33188364) Diabetes Ther. 2021 Nov;12(11):2857-2870. (PMID: 34398433) Diabetes Metab Syndr. 2021 Mar-Apr;15(2):513-518. (PMID: 33662839) Diabetes Care. 2020 Jul;43(7):1399-1407. (PMID: 32409498) Clin Exp Immunol. 2016 Jul;185(1):1-21. (PMID: 26919392) Diabetes Care. 2020 Dec;43(12):2999-3006. (PMID: 32994187) Diabetes Obes Metab. 2021 Jun;23(6):1397-1401. (PMID: 33502076) Diabetes Care. 2020 Dec;43(12):3042-3049. (PMID: 33023989) Diabetes Ther. 2021 Dec;12(12):3037-3054. (PMID: 34699021) Nutr Metab Cardiovasc Dis. 2021 Feb 8;31(2):396-398. (PMID: 33223405) Int J Mol Sci. 2021 Nov 03;22(21):. (PMID: 34769350) Diabetes. 2021 Dec;70(12):2903-2916. (PMID: 34580086) Emerg Microbes Infect. 2020 Dec;9(1):601-604. (PMID: 32178593) Front Pharmacol. 2021 Dec 09;12:731453. (PMID: 34955820) Am J Respir Crit Care Med. 2018 Aug 15;198(4):509-520. (PMID: 29570986) JCI Insight. 2020 Mar 26;5(6):. (PMID: 32213703) Endocrinol Metab (Seoul). 2021 Aug;36(4):904-908. (PMID: 34311543) Front Endocrinol (Lausanne). 2021 Sep 16;12:708494. (PMID: 34603199) Prim Care Diabetes. 2021 Oct;15(5):806-812. (PMID: 34376379) Diabetologia. 2020 Aug;63(8):1500-1515. (PMID: 32472191) BMJ Open. 2021 Oct 20;11(10):e052310. (PMID: 34670765) J Endocrinol Invest. 2021 Jul;44(7):1379-1386. (PMID: 33512688) World J Virol. 2021 Jul 25;10(4):182-208. (PMID: 34367933) PLoS One. 2021 May 20;16(5):e0251916. (PMID: 34015003) J Diabetes Metab Disord. 2021 Jun 26;20(2):1155-1160. (PMID: 34222054) Diabetes Metab. 2021 Jul;47(4):101208. (PMID: 33160030) Eur J Clin Invest. 2020 Dec;50(12):e13339. (PMID: 32648935) Diabetes Res Clin Pract. 2021 Mar;173:108619. (PMID: 33310173) Diabetes Obes Metab. 2021 Jul;23(7):1696-1700. (PMID: 33606909) Med Hypotheses. 2022 Jan;158:110739. (PMID: 34916733) Diabetes Obes Metab. 2020 Oct;22(10):1946-1950. (PMID: 32463179) Endocr Rev. 2014 Dec;35(6):992-1019. (PMID: 25216328) |
| فهرسة مساهمة: | Keywords: COVID-19; DPP-4 inhibitors; DPP-4抑制剂; GLP-1RA; SGLT-2 inhibitors; SGLT-2抑制剂; diabetes; oral antihyperglycemic; sulfonylureas; thiazolidinediones; 口服降糖药物; 噻唑烷二酮类; 新型冠状病毒肺炎; 磺脲类; 糖尿病 Local Abstract: [Publisher, Chinese] 背景:糖尿病患者更易罹患COVID-19并发症。在COVID-19感染期间使用非胰岛素降糖药物(AGMs)具有挑战性。在本研究中, 我们评估了COVID-19患者的不同非胰岛素降糖药物。 方法:检索Medline、Embase、Web of Science和Cochrane数据库, 检索时间截至2022年1月24日。我们使用了以下关键词:COVID-19、糖尿病和降糖药。纳入标准为报告一项或多项结局的研究, 并排除非英文文献、病例报告和文献综述。研究结局包括死亡率、住院和入住ICU。 结果:与其他降糖药物相比, 使用二甲双胍与显著较低的死亡率相关(风险比[RR] 0.60,95% CI 0.47,0.77,p<0.001)。与非使用者相比, 使用DPP-4i与较高的住院风险(RR 1.44, 95% CI 1.23, 1.68, p<0.001)和较高的ICU入住和/或机械通气风险(RR 1.24, 95% CI 1.04, 1.48, p<0.02)相关。SGLT-2i用药者的住院率显著低于非用药者(RR 0.89, 95% 0.84 -0.95, p <0.001)。胰高血糖素样肽-1受体激动剂(GLP-1RA)的使用与死亡率(RR 0.56, 95%CI, 0.42, 073, p<0.001)、入住ICU和/或机械通气(RR 0.79, 95%CI, 0.69- 0.89, p<0.001)和住院(RR 0.73, 95%CI 0.54, 0.98, p=0.04)显著降低相关。 结论:AGMs的使用与死亡率增加无关。二甲双胍和GLP-1RA的使用显著降低了死亡率风险。DPP-4i的使用与住院和入住ICU的风险显著增加相关。. |
| المشرفين على المادة: | 0 (Hypoglycemic Agents) 0 (Sodium-Glucose Transporter 2 Inhibitors) 0 (Dipeptidyl-Peptidase IV Inhibitors) 9100L32L2N (Metformin) 0 (Glucagon-Like Peptide-1 Receptor) |
| تواريخ الأحداث: | Date Created: 20230123 Date Completed: 20230222 Latest Revision: 20230222 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9934962 |
| DOI: | 10.1111/1753-0407.13359 |
| PMID: | 36690377 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!